Summary of Key Points
The recent significant financings by Yaotang Biology (intra-body gene editing) and Ruijian Medicine (cell reprogramming) mark a reversal in the trend of the primary biopharmaceutical market: previously, capital focused on companies in the clinical phase or CROs (contract research organizations), but now it is flowing back towards foundational technology platforms. This shift is driven by three main factors—technological maturity, the aging population, and policy support. Moreover, the cost and pricing model of intra-body gene editing have the potential to disrupt existing treatments, demonstrating long-term value for investors.
Detailed Analysis
#### 1. A Major Shift in Market Trend: From “急于 Cash Out” to “Betting on the Future”
In the past two years, the biopharmaceutical market was sluggish, with investors asking two primary questions upon meeting: “Are there any developments in partnerships with large companies (BD)?” and “How long will the funds last?” Early-stage technology companies, such as those working in gene editing and cell reprogramming, were labeled as having overly ambitious ideas and difficult exit strategies, making it hard for them to secure funding.
However, Yaotang’s nearly 500 million RMB in Series C financing and Ruijian’s 210 million RMB in Series C1 financing indicate a change in investor sentiment. They are no longer solely interested in projects that can generate immediate profits but are willing to invest in foundational technologies that could transform the industry in the future.
#### 2. Intra-Body Gene Editing: A More Practical “Black Technology”
In vitro gene editing (e.g., CAR-T therapy) involves extracting patient cells, modifying them in the lab, and then reinfusing them into the patient. This process requires cold-chain transportation and close medical supervision, costing hundreds of thousands of dollars per treatment, which is unaffordable for most people.
Intra-body gene editing, on the other hand, is much simpler: the genetic editing tools are directly delivered to the target cells within the patient’s body, eliminating the need for external manipulations. If safety is established, costs are expected to decrease significantly—this is similar to shifting from custom-made suits to mass-produced clothing, making the technology more accessible. This is precisely why investors are optimistic about its potential.
#### 3. Three Key Drivers Behind the Revival of Fundamental Technologies
There are three main reasons why investors are now willing to invest in foundational technologies:
- Technological Progress: Gene editing tools have become more precise (from CRISPR to base editing, with fewer errors), and delivery systems (such as lipid nanoparticles) have improved, allowing targeted delivery to organs like the liver and brain. Investors no longer question whether the technology is feasible but focus on its therapeutic potential and safety.
- The Aging Population: China has over 200 million people aged 65 and above, with 3 million suffering from Parkinson’s disease. Current treatments can only alleviate symptoms, not cure the root causes. Gene editing and cell therapies offer a chance to address these underlying issues, creating a strong demand.
- Policy Support: New regulations implemented in 2026 have clarified the approval process for intra-body gene editing, providing a stable regulatory framework. Investors are no longer concerned about investing in technologies that may not pass review, thus they are more willing to take the leap.
#### 4. Pricing Models on the Brink of Change: From “Exorbitant One-Time Fees” to More Affordable Access
Currently, gene therapy treatments cost anywhere from $1 million to $3 million per session worldwide. However, intra-body gene editing has a significant advantage in terms of scalability: treatments can be produced in bulk, eliminating the need for personalized customization. As production volumes increase, costs will decrease significantly (for example, producing 1,000 treatments versus 100,000). In the future, pricing may shift from high one-time fees to more affordable options based on treatment duration, disease type, and region, making the technology more widely accessible. Investors are betting on the potential to disrupt existing treatments and business models—after all, only technologies that truly benefit a broader audience have real value.
These financings are not incidental but signify the transition of foundational technologies from laboratory concepts to clinical applications. Once technology, demand, and policy are all in place, the influx of capital is just a matter of time. The era of innovative, high-tech pharmaceuticals may be upon us.